Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 14;9(8):e104610.
doi: 10.1371/journal.pone.0104610. eCollection 2014.

ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia

Zi-Jie Long  1 , Yuan Hu  1 , Xu-Dong Li  1 , Yi He  1 , Ruo-Zhi Xiao  1 , Zhi-Gang Fang  1 , Dong-Ning Wang  1 , Jia-Jun Liu  1 , Jin-Song Yan  2 , Ren-Wei Huang  1 , Dong-Jun Lin  1 , Quentin Liu  3
Affiliations

ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia

Zi-Jie Long et al. PLoS One. .

Abstract

The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3, ATO) has been effective in obtaining high clinical complete remission (CR) rates in acute promyelocytic leukemia (APL), but the long-term efficacy and safety among newly diagnosed APL patients are unclear. In this retrospective study, total 45 newly diagnosed APL patients received ATRA/chemotherapy combination regimen to induce remission. Among them, 43 patients (95.6%) achieved complete remission (CR) after induction therapy, followed by ATO/ATRA/anthracycline-based chemotherapy sequential consolidation treatment with a median follow-up of 55 months. In these patients, the estimated overall survival (OS) and the relapse-free survival (RFS) were 94.4% ± 3.9% and 94.6 ± 3.7%, respectively. The toxicity profile was mild and reversible. No secondary carcinoma was observed. These results demonstrated the high efficacy and minimal toxicity of ATO/ATRA/anthracycline-based chemotherapy sequential consolidation treatment for newly diagnosed APL in long-term follow-up, suggesting a potential frontline therapy for APL.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. A chart review of patients treated with standard of induction and consolidation therapy.
Figure 2
Figure 2. Survival analysis.
The OS for all 45 patients.
Figure 3
Figure 3. Survival analysis.
The OS (A) and RFS (B) for the 43 patients who obtained CR.
See this image and copyright information in PMC

References

    1. Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111: 2505–2515. - PubMed
    1. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, et al. (1989) Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 73: 1116–1122. - PubMed
    1. Sanz MA, Jarque I, Martín G, Lorenzo I, Martínez J, et al. (1988) Acute promyelocytic leukemia: therapy results and prognostic factors. Cancer 61: 7–13. - PubMed
    1. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, et al. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567–572. - PubMed
    1. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, et al. (2002) All-trans retinoic acid in acute promyelocytic leukemia: Longterm outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100: 4298–4302. - PubMed

MeSH terms

LinkOut - more resources